Observational Study of Clonal Hematopoiesis and Neoadjuvant Immunotherapy Efficacy in Lung Cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600128415

Enrollment

Unknown

Registered

2026-07-20

Start date

2024-11-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer, stage IB–IIIA

Interventions

CH Negative Group:None

CH Positive Group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. pathologically confirmed NSCLC (including squamous cell carcinoma and adenocarcinoma), stage IB–IIIA; 3. planned neoadjuvant immunotherapy (e.g., PD-1/PD-L1 inhibitors) with follow-up; 4. written informed consent;

Exclusion criteria

Exclusion criteria: 1. Patients who cannot tolerate immunotherapy.

Design outcomes

Primary

Measure	Time frame
Major Pathological Response (MPR, residual tumor <=10%);	—

Secondary

Measure	Time frame
Incidence of immune-related adverse events;Progression-Free Survival;Overall Survival;	—

Countries

China

Contacts

Public ContactChen Jian

Shanghai Pulmonary Hospital

yufuchenjian@tongji.edu.cn+86 21 6511 5006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026